RealTime Dynamix™: Psoriatic Arthritis US Q2 2018 Spotlight

RealTime Dynamix™: Psoriatic Arthritis US Q2 2018 Spotlight

The rheumatologist user base for Eli Lilly’s Taltz in PsA has exhibited strong growth from Q1 to Q2, while use of Pfizer’s Xeljanz has remained flat over the past quarter, according to 100 US rheumatologists surveyed in Q2 2018. See complimentary highlights from the most recent wave of RealTime Dynamix™: Psoriatic Arthritis US below.

Contact [email protected] for more information about the highlighted report or to see if your company already has access to the report series.

All company, brand or product names and logos in this document are trademarks of their respective holders.

Join Our Newsletter

This website intends to use cookies to improve the site and your experience. By continuing to browse the site you are agreeing to accept our use of cookies. If you require further information and/or do not wish to have cookies placed when using the site, visit About Cookies page.OKREAD MORE